Following these proceedings, Citigroup upgraded its Summit Therapeutics Inc [SMMT] rating to a Buy from a a Neutral in a research note published on March 26, 2025; the price target was increased to $35 from $23. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late March with a ‘”an Overweight”‘ rating. Evercore ISI began covering SMMT with “an Outperform” recommendation on March 12, 2025. Goldman started covering the stock on February 28, 2025. It rated SMMT as “a Buy”.
Price Performance Review of SMMT
On Monday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock jump 0.43% to $28.02. Over the last five days, the stock has gained 16.22%. Summit Therapeutics Inc shares have risen nearly 57.02% since the year began. Nevertheless, the stocks have risen 496.17% over the past one year. While a 52-week high of $36.91 was reached on 04/24/25, a 52-week low of $2.10 was recorded on 04/07/25. SMA at 50 days reached $21.47, while 200 days put it at $19.04.
Levels Of Support And Resistance For SMMT Stock
The 24-hour chart illustrates a support level at 27.06, which if violated will result in even more drops to 26.10. On the upside, there is a resistance level at 28.63. A further resistance level may holdings at 29.24. The Relative Strength Index (RSI) on the 14-day chart is 57.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.46%. Stochastics %K at 35.07% indicates the stock is a holding.
The most recent change occurred on January 08, 2025 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
